Axcella Health (AXLA) Tops Q1 EPS by 2c

Axcella Health (NASDAQ: AXLA) reported Q1 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42).

“Already in 2021, we have made tremendous progress in advancing our EMM platform and our mission to bring new multi-targeted therapies to patients with complex diseases and conditions,” said Bill Hinshaw, President and Chief Executive Officer of Axcella. “The recent clearance of our first two investigational new drug (IND) applications has extended our strong track record of execution. Additionally, these milestones validate how we can efficiently compile a significant amount of clinical data and then rapidly progress into later-stage development. We expect to continue our momentum as we get our later-stage clinical trials in overt hepatic encephalopathy (OHE) and nonalcoholic steatohepatitis (NASH) underway this quarter, ramp up enrollment leveraging a physician network that is excited by our approach and modality, and expand Axcella’s pipeline of EMM compositions.”

For earnings history and earnings-related data on Axcella Health (AXLA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Cable One names Heather McCallion as chief operating officer
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c